Anavex Life Sciences Corp. said the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion on its marketing-authorisation application for blarcamesine—an investigational oral treatment for early Alzheimer’s disease. The CHMP’s decision follows a negative trend-vote after an oral examination in November, indicating the committee concluded that the current data package did not sufficiently demonstrate the drug’s effectiveness and safety for this indication.
In response to the negative opinion, Anavex said it intends to request a re-examination of the CHMP decision. Under EMA procedures, a re-examination involves a new set of reviewers conducting an independent assessment of the application; this offers the company another opportunity to present its clinical evidence and address regulatory concerns. Anavex emphasised that this update reflects ongoing dialogue with regulators and a shared focus on addressing the unmet need in Alzheimer’s disease care.
The company noted that the press release discusses investigational uses of blarcamesine and does not imply conclusions about the drug’s efficacy or safety, and there is no guarantee of eventual approval in the EU. Blarcamesine (ANAVEX®2-73) has completed Phase 2a and Phase 2b/3 clinical trials in Alzheimer’s disease and has been studied in other central nervous system indications in earlier stages, but regulatory outcomes remain uncertain pending further review.
Alzheimer’s disease—the most common cause of dementia—continues to present a substantial unmet medical need, as current therapies offer limited benefits and researchers seek more effective treatments to slow or modify disease progression.
